The cardiovascular health activities are in response to the growing burden of these diseases due to the social, demographic, epidemiologic and health care transitions that have led to cardiovascular diseases being the number one cause of death in the country.
The activities are dedicated to:
| Sl No. | Title | Authors | Journal Name | Publication Year |
|---|---|---|---|---|
| 91 | Comparison of Nonblood-Based and Blood-Based Total CV Risk Scores in Global Populations | Gaziano TA, Abrahams-Gessel S, Alam S, Alam D, Ali M, Bloomfield G, Carrillo-Larco RM, Dorairaj P, Gutierrez L, Irazola V, Levitt NS, Miranda JJ, Bernabe-Ortiz A, Pandya A, Rubinstein A, Steyn K, Xavier D, Yan LL | Glob Heart | 2016 |
| 92 | Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study | Healey JS, Oldgren J, Ezekowitz M, Zhu J, Pais P, Wang J, Commerford P, Jansky P, Avezum A, Sigamani A, Demasceno A, Reilly P, Grinvalds A, Nakamya J, Aje A, Almahmeed W, Moriarty A, Wallentin L, Yusuf S, Connolly SJ | Lancet | 2016 |
| 93 | Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data | Khatib R, McKee M, Shannon H, Chow C, Rangarajan S, Teo K, Wei L, Mony P, Mohan V, Gupta R, Kumar R, Vijayakumar K, Lear SA, Diaz R, Avezum A, Lopez-Jaramillo P, Lanas F, Yusoff K, Ismail N, Kazmi K, Rahman O, Rosengren A, Monsef N, Kelishadi R, Kruger A, Puoane T, Szuba A, Chifamba J, Temizhan A, Dagenais G, Gafni A, Yusuf S | Lancet | 2016 |
| 94 | Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease | Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, et al. | N Engl J Med | 2016 |
| 95 | Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease | Yusuf S, Bosch J.,Dagenais G, Zhu J, *Xavier D*, Liu L, *Pais P*, López-Jaramillo P, Leiter LA, et al., | The New England Journal of Medicine | 2016 |
| 96 | Non-physician health workers for improving adherence to medications and healthy lifestyle following acute coronary syndrome: 24-month follow-up study | KK Sharma, R Gupta, *M Mathur*, V Natani, S Lodha, S Roy, *D Xavier*. | Indian Heart Journal | 2016 |
| 97 | Clinical events after transitioning from apixaban versus warfarin to warfarin at the end of the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial | Christopher B. Granger, Renato D. Lopes, Michael Hanna, Jack Ansell, Elaine M. Hylek, John H. Alexander, Laine Thomas, Junyuan Wang, M. Cecilia Bahit, Freek Verheug, Jack Lawrence, *Denis Xavier*, Lars Wallentin. | American Heart Journal January | 2015 |
| 98 | Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: The PURE study | Gupta R, Islam S, Mony P, Kutty VR, Mohan V, Kumar R, Thakur J, Shankar VK, Mohan D, Vijayakumar K, Rahman O, Yusuf R, Iqbal R, Shahid M, Mohan I, Rangarajan S, Teo KK, Yusuf S | Eur J Prev Cardiol | 2015 |
| 99 | Urinary sodium and potassium excretion, mortality, and cardiovascular events | O'Donnell M, Mente A, Rangarajan S, McQueen MJ, Wang X, Liu L, Yan H, Lee SF, Mony P, Devanath A, et al | N Engl J Med | 2014 |
| 100 | Treatment with B vitamins and incidence of cancer in patients with previous stroke or transient ischemic attack: results of a randomized placebo-controlled trial | Hankey G, Eikelboom JW, Yi Q, Lees KR, Chen C, Xavier D, Navarro JC, Ranawaka UK, Uddin W, Ricci S, Gommans J, Schmidt R; VITAmins TO Prevent Stroke (VITATOPS) Trial Study Group | Stroke | 2012 |
| 101 | Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey | Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK; Prospective Urban Rural Epidemiology (PURE) Study Investigators | Lancet | 2011 |
| 102 | The need to test the theories behind the Polypill: rationale behind the Indian Polycap | *Xavier D*, *Pais P*, Sigamani A, Pogue J, Afzal R, Yusuf S; Indian Polycap Study (TIPS) Investigators | Nat Clin Pract Cardiovasc Med | 2009 |
| 103 | VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke. | VITATOPS Trial Study Group; Hankey GJ, Algra A, Chen C, Wong MC, Cheung R, Xavier D, et al. | Int J Stroke | 2007 |
| 104 | Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery. | Devereaux PJ, Yang H, Guyatt GH, Pais P, Xavier D, Yusuf S, et al. | Am Heart J | 2006 |